Letter by Koh Regarding Article, "Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?"

被引：1
|
作者：
Koh, Kwang Kon [1 ,2 ]
机构：
[1] Gachon Univ, Gil Med Ctr, Heart Ctr, Dept Cardiovasc Med, Seongnam Si, Gyeonggi Do, South Korea
[2] Gachon Cardiovas Res Inst, Incheon, South Korea
来源：
CIRCULATION | 2017年 / 135卷 / 17期
关键词：
SIMVASTATIN; RISK;
D O I：
10.1161/CIRCULATIONAHA.116.026821
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E1006 / E1007
页数：2
相关论文
共 50 条
  • [1] Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner, Vera
    CIRCULATION, 2016, 134 (22) : 1695 - 1696
  • [2] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [3] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
  • [4] Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
    Shahreyar, Muhammed
    Salem, Salem A.
    Nayyar, Mannu
    George, Lekha K.
    Garg, Nadish
    Koshy, Santhosh K. G.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2018, 31 (04) : 628 - 634
  • [5] Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
    Filippatos, Theodosios D.
    Christopoulou, Eliza C.
    Elisaf, Moses S.
    CURRENT OPINION IN LIPIDOLOGY, 2018, 29 (04) : 333 - 339
  • [6] PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
    Shimada, Yuichi J.
    Cannon, Christopher P.
    EUROPEAN HEART JOURNAL, 2015, 36 (36) : 2415 - U36
  • [7] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
  • [8] Regulation of ENaC by proprotein convertase subtilisin/kexin type 9(PCSK9)
    Sharotri, Vikas
    Snyder, Peter M.
    FASEB JOURNAL, 2010, 24
  • [9] Neurological Effects of Proprotein Convertase Subtilisin/kexin Type 9(PCSK9) Inhibitors: Direct and Indirect Comparisons
    Patel, Nirav
    Kalra, Rajat
    Venkatraman, Anand
    Godara, Hemant
    Arora, Garima
    Bajaj, NavKaranbir S.
    Arora, Pankaj
    CIRCULATION, 2016, 134
  • [10] PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes "DAMP"
    Silverstein, Roy L.
    CIRCULATION, 2021, 143 (01) : 62 - 64
12345